North America is expected to holda dominant position in the cell expansion market due to increasing demand forregenerative medicines and rising incidence of chronic diseases
Regional segmentation of the CellExpansion Market by Coherent Market Insights includes North America, LatinAmerica, Europe, Asia Pacific, Middle East, and Africa. The cell expansionmarket in North America is driven by the increasing demand for regenerativemedicines that are highly compatible with patients and offer rapid results. Forinstance, the FDA is increasingly approving treatments involving cells derivedfrom bone or blood marrow, due to its well-established efficacy and safety.Furthermore, increasing incidence of chronic diseases and rising R&Dinvestments for the development of cell-based products are other factorsexpected to support growth of the cell expansion market. For instance in 2018,according to the Centers for Disease Control and Prevention approximately 6 in10 American citizen have at least one chronic diseases such as cancer,diabetes, and others in the U.S.
According to a study published inNIH report, around 500,000 people benefit from a transplant each year usingregenerative medicine in the U.S. Increasing R&D expenditure by severalcompanies for the development of new therapeutic products and availability ofuntapped growth opportunities are expected to drive the cell expansion marketin Asia Pacific. For instance, according to the Indian Brand Equity Foundationreports the Government of India the healthcare expenditure is approximately 1.4% of total GDP in 2018 as compared to 1.2% in 2014.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1293
Cell expansion is the large scaleartificial production of daughter cells from a single cell, to support medicalresearch. Rising preference for regenerative medicines offering faster results,and emergence of cell-based therapies with high patient compatibility areexpected to fuel the cell expansion market during the forecast period(2017–2025). Regenerative medicine helps the body to form new functional tissueto replace defective or lost ones providing treatment for conditions withinadequate therapies. According to the U.S. Department of Health and Services,in 2016, NIH invested around US$ 1.5 billion in stem cell research projects.Increasing government and private sector expenditure on cell-based researchtherapies is expected to boost growth of the market for cell expansion in thenear future. The number of FDA approvals for clinical trials of stem cell-basedtreatments is rapidly increasing. According to a report published byPharmaceutical Research and Manufacturers of America, in 2013, around 69 celltherapies with clinical trials were under review with the FDA. The therapeuticclasses represented in these trials include skin diseases, cardiovasculardiseases, transplantations, eye conditions, cancer and associated conditions,musculoskeletal disorders, genetic disorders, and digestive disorders.
Increasing incidence of chronicmedical conditions is expected to boost growth of the cell expansion marketover the forecast period
The increasing cases of chronicand rare medical conditions around the world is another key factor drivingdemand for cell expansion. For instance, according to World Health Organization(WHO), around 15 million people are projected to suffer from cancer by 2020.The rising prevalence of cancer, is in turn, expected to boost growth of thecell expansion market. Cell-based therapy is also a promising approach fortreating chronic kidney disease and is presently the focus of preclinicalstudies.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/cell-expansion-market-1293
Recent advancements inregenerative medicine and tissue engineering have created cell-based approachesfor the treatment of renal failure. Such treatments include biotechnologicalapproach using implantation of bioengineered kidney constructs, transplantingcells, and bio-artificial renal systems. However, lack of high-techinstrumentation and skilled workforce coupled with the high cost of operationsare expected to hamper growth of the cell expansion market.
Biotechnology merger andacquisition (M&A) activities have also experienced a boost in the region.According to investment bank China Renaissance, in 2016, 37 pharmaceutical andbiotech M&A deals worth US$ 6.8 billion were closed in China.
Major industry players use mergerand acquisitions as their major growth strategy
Key players operating in the cellexpansion market include Becton, Dickinson and Company, Beckman Coulter, Inc.,Corning, Inc., GE Healthcare, Lonza, Merck KGaA (Sigma-Aldrich Co. LLC),Miltenyi Biotec, Thermo Fisher Scientific, Inc., Terumo BCT, Inc., and StemcellTechnologies, Inc. In July 2016, GE Healthcare acquired Biosafe SA, a Swisscompany that manufactures instruments that recover stem cells and help invarious other cell processing procedures related to personalized medicine. Thisacquisition will help GE Healthcare to grow the cells in the sample forappropriate dose sizes.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1293
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
